Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01005407 · ClinicalTrials.gov registry record · Phase 3
Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine
A Phase 3 study, sponsored by Dynavax Technologies Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,452
- Enrollment target
NCT01005407 is a Phase 3 study that has completed, run by Dynavax Technologies Corporation. The registered enrollment target is 2,452 participants.
The verdict
NCT01005407, a Phase 3 study, has completed, sponsored by Dynavax Technologies Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,452 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety, immunogenicity and lot-to-lot consistency of an investigational hepatitis B virus vaccine, HEPLISAV™, in healthy adults 40 to 70 years of age
Interventions
- BIOLOGICAL Engerix-B
- BIOLOGICAL HEPLISAV and/or Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,452 participants |
| Start Date | 2010-02 |
| Est. Completion | 2011-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01005407
The ClinicalTrials.gov registry entry for NCT01005407 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,452 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dynavax Technologies Corporation, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Engerix-B is the first listed.
NCT01005407 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01005407 about?
NCT01005407 is a clinical study titled "Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine". The purpose of the study is to evaluate the safety, immunogenicity and lot-to-lot consistency of an investigational hepatitis B virus vaccine, HEPLISAV™, in healthy adults 40 to 70 years of age
What is the current status of trial NCT01005407?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,452 participants. The study started on 2010-02. Estimated completion is 2011-05.
What interventions are being tested in trial NCT01005407?
The interventions under investigation include: Engerix-B (BIOLOGICAL), HEPLISAV and/or Placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT01005407?
This trial is sponsored by Dynavax Technologies Corporation, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.